According to research presented today at the American Society for Radiation Oncology's (ASTRO's) 55th Annual Meeting, being held in Atlanta,September 22-25, 2013, early-stage breast cancer patients who receive external beam therapy or XRT are not at higher risk for serious long-term side effects in the chest area, including increase in deaths from cardiac disease and secondary malignancies.
Various studies have shown that…Continue
Added by Peter Hofland, PhD on September 24, 2013 at 8:30am — No Comments
Results of a study presented today at the American Society of Radiation Oncology's (ASTRO's) 55th Annual Meeting held in Atlanta, September 22-25, 2013 shows that Sulfasalazine (Azulfidine®, Pfizer), a drug commonly prescribed to reduce diarrhea in patients with rectal bleeding and abdominal pain in patients with ulcerative colitis, a condition in which the bowel is inflamed, does not reduce diarrhea in patients receiving radiation therapy for cancers in the pelvic area. The study…Continue
Added by Peter Hofland, PhD on September 24, 2013 at 6:00am — No Comments
Breast cancer is the most common cancer among women worldwide. According to the American Cancer Society (ACS), approximately 235,000 women in the United States will be diagnosed with breast cancer. Based on long-term data, it is expected that in 2013 40,000 will die from the disease in the U.S. alone. 
Once breast cancer becomes metastatic, it is…Continue
Added by Peter Hofland, PhD on September 19, 2013 at 6:00pm — No Comments
Despite the success of recent approved therapeutics to treat advanced melanoma, metastatic cancer cells inevitably evolve resistance to drugs. In the September 19. 2013 edition of the journal Cell Reports, a team of researchers based at The Wistar Institute in Philadelphia, PA (USA), report on the mechanics by which melanoma can evolve resistance to a powerful combination of drugs — BRAF and MEK…Continue
Added by Peter Hofland, PhD on September 19, 2013 at 4:30pm — No Comments
For more than a century scientists have been searching for noninvasive technologies to peer deep inside the human body by using light. With much interests, healthcare professionals involved in the management of patients with cancer, want to see inside the body because they are interested in understanding the numerous subtle and often invisible changes to the human DNA, proteins, cells, and tissue involved in altering the body's normal biology.
For the first time, a team of…Continue
Added by Peter Hofland, PhD on September 17, 2013 at 2:00pm — No Comments
Tissue-conserving cancer surgery is used increasingly in cancer treatment. It is a highly skilled procedure. One of the main challenges in this type of surgery is the detection of tumor margins which involves time-consuming tissue preparation. The goal of tissue-conserving cancer surgery is to remove as much of the tumour as possible while sparing healthy tissue.
Histopathology, which refers to the examination of a biopsy or surgical specimen by a pathologist, and is based on…Continue
Added by Peter Hofland, PhD on September 17, 2013 at 11:30am — No Comments
The U.S. Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) voted 13 to 0, with one abstention, in favor of recommending accelerated approval of a regimen of pertuzumab (Perjeta®, Genentech/Roche) for neoadjuvant treatment in women with high-risk, HER2-positive early stage breast cancer.
Breast cancer is the most common cancer among women worldwide.…Continue
Added by Peter Hofland, PhD on September 12, 2013 at 8:00pm — No Comments
Tiny particles called nanodiamonds (NDs) are very promising candidates in nanomedicine. Researchers have demonstrating that nanodiamonds offer a significant potential as gene/drug delivery platforms in the treatment of cancer. While the potential of nanodiamond in drug delivery has been demonstrated, fundamental mechanisms, thermodynamics, and kinetics of drug adsorption on nanodiamond are still poorly understood.
In a study, supported by a National Science Foundation CAREER…Continue
Added by Peter Hofland, PhD on September 11, 2013 at 6:30pm — No Comments
Findings presented at the European Respiratory Society (ERS) Annual Congress, being held in Barcelona, Spain (September 7 - 11, 2013), shows that collecting samples of exhaled breath from people at a high risk of lung cancer could be a cheap and non-invasive method of diagnosing the disease, according to new research.
Current tests for lung cancer include blood and urine tests, followed by CT scans and chest…Continue
Added by Peter Hofland, PhD on September 9, 2013 at 10:00pm — No Comments
Natural Killer (NK) cells, a component of our innate immune system, are a type of lymphocyte designed to play a major role in defending our bodies in the host-rejection of both virally infected cells and cancer cells, thus protecting our bodies from harm.
Now, for the first time, scientists at Vetmeduni, the University of Veterinary Medicine, Vienna, Austria, show that NK-cell activity can be influenced by…Continue
Ductal carcinoma in situ or DCIS, a precursor of breast cancer, usually found during a mammogram as part of breast cancer screening, is the presence of abnormal cells inside a milk duct in the breast. While noninvasive and not life-threatening, it may progress to invasive breast cancer if left untreated and therefor requires treatment.…Continue
Added by Peter Hofland, PhD on September 5, 2013 at 12:30pm — No Comments
Results of a study by scientists at Johns Hopkins which was funded by the National Cancer Institute, identify a molecular marker called mitogen-inducible gene 6 or Mig6, a negative regulator of EGFR through the upregulation of the PI3K-AKT pathway. This molecular marker appears to accurately predict longer survival among patients prescribed two of the most widely used drugs in a class of anticancer agents called EGFR-inhibitors. These preliminary results need further…Continue
Added by Peter Hofland, PhD on September 5, 2013 at 10:00am — No Comments
The immune system is a collection of reactions and responses protecting our bodies from harm of infection and illness caused by bacteria, viruses, fungi or parasites. The body's primary in-built protection, the
innate immunity, is always ready and prepared to act immediately. A second mechanism, the acquired immunity, learns from being exposed to diseases and creates an immune memory for future defense. These 'good' systems keep us healthy.
But a new…Continue
Added by Peter Hofland, PhD on September 5, 2013 at 9:00am — No Comments
A new injectable (subcutaneous) formulation of trastuzumab (Herceptin; Roche/Genentech) has been approved by the European Commission for the treatment of HER2-positive breast cancer, an aggressive sub-type of the disease. The approval is for both early and later stages of treatment.
“More than 90,000 women in Europe are diagnosed with HER2 positive breast cancer every year,” said Hal Barron, MD, Chief Medical Officer and Head of Global Product Development at Roche. “This new,…Continue
Added by Peter Hofland, PhD on September 2, 2013 at 10:00pm — No Comments
Phase III clinical trial results from PRELUDE study, which explored the enzastaurin (Eli Lilly and Company; Lilly Oncology) as a monotherapy in the prevention of relapse in patients with diffuse large B-cell lymphoma (DLBCL), failed to show a statistically significant increase compared to placebo…Continue
Added by Peter Hofland, PhD on May 10, 2013 at 6:00am — No Comments
A new multi-center trial of high dose Interleukin-2 (HD rIL-2; Aldesleukin for Injection/Proleukin®; Prometheus Laboratories Inc, San Diego, CA/Novartis Vaccines and Diagnostics, Emeryville, CA) plus vemurafenib (Zelboraf®, Genentech/Roche) therapy in patients with BRAF V600 mutation-positive…Continue
Added by Peter Hofland, PhD on May 9, 2013 at 10:00am — No Comments
Data from various cancer registries in the United Kingdom shows that Bladder Cancer is a common cancer among men and women in the United Kingdom, with 10.335 new cases diagnosed in 2008.  It is one of the most frequently diagnosed cancer of the urinary system and accounts for 1 in every 30 new cases. With 7,390 new cases diagnosed in 2008, is a the 4th most common cancer in men  and 11th in women (2,945 female cases), giving a male: female ration of…Continue
Added by Peter Hofland, PhD on May 7, 2013 at 9:30pm — No Comments
Date presented at the 2013 Conference of The American Society of Breast Surgeons (ASBrS) shows promising results for non-surgical cryoablation treatment of breast cancer. The results were presented by Eisuke Fukuma, M.D., Ph.D., Chairman and Director of Breast Center, Director of Breast Disease Kameda Medical Center in Kamogawa City, Chiba, Japan.
Cryoablation, also be called percutaneous ablation,…Continue
Added by Peter Hofland, PhD on May 7, 2013 at 5:30pm — No Comments
Results of the ASPECCT ('763) trial, a phase III head-to-head study evaluating panitumumab (Vectibix®; Amgen Inc.) versus cetuximab (Erbitux®; ImClone LLC/Eli Lilly and Company and Bristol-Myers Squibb Company) as a single agent for the treatment of chemorefractory metastatic colorectal cancer (mCRC) in patients with wild-type KRAS tumors (n=1,010) met its primary endpoint…Continue
Added by Peter Hofland, PhD on May 7, 2013 at 3:00pm — No Comments
Results from a Phase II trial shows that ibrutinib (also known as PCI-32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; Janssen Biotech, Inc. and Pharmacyclics), a first-in-class oral therapy that is a selective, irreversible, inhibitor of Bruton’s tyrosine kinase (BTK), offers rapid and sustained disease control as a monotherapy in untreated, relapsed and refractory chronic lymphocytic leukemia (CLL) patients, irrespective of…Continue
Added by Peter Hofland, PhD on April 8, 2013 at 11:00am — No Comments